Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

In particular, Lilly highlighted the momentum behind breast cancer med Verzenio and the SGLT2 inhibitor Jardiance, which generated roughly $1.6 billion and $1.2 billion in 2024’s fourth quarter ...

Revenue from the breast cancer treatment Verzenio also helped, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced 45% to $13.53 billion ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. Sales of Verzenio (a breast cancer drug) increased 32% to $1.37 billion, and sales of diabetes drug Jardiance fell ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...